Wellington Shields Capital Management LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,867 shares of the biopharmaceutical company’s stock after selling 800 shares during the period. Wellington Shields Capital Management LLC’s holdings in Gilead Sciences were worth $344,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Hall Laurie J Trustee raised its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Penserra Capital Management LLC raised its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Finally, Webster Bank N. A. raised its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. 74.04% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.864% on Tuesday, hitting $75.335. The stock had a trading volume of 6,082,296 shares. The firm has a market cap of $98.38 billion, a P/E ratio of 8.182 and a beta of 1.21. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.07. The firm’s 50-day moving average price is $72.97 and its 200-day moving average price is $68.87. Gilead Sciences also was the recipient of some unusual options trading on Monday. Stock investors acquired 19,878 put options on the company. This is an increase of approximately 209% compared to the typical daily volume of 6,434 put options.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.08 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post $8.74 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.78%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is presently 22.58%.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/wellington-shields-capital-management-llc-lowers-position-in-gilead-sciences-inc-gild/1530128.html.

GILD has been the topic of several research reports. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target on the stock in a research report on Tuesday, May 2nd. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.34 price target on the stock. in a research report on Thursday, May 11th. Stifel Nicolaus reissued a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Gabelli reissued a “buy” rating and set a $85.00 price target on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Finally, Deutsche Bank AG initiated coverage on Gilead Sciences in a research report on Friday, June 23rd. They set a “buy” rating and a $79.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $80.83.

In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the transaction, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 206,666 shares of company stock worth $15,223,184. Company insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.